



TheraCarb Inc. Receives Notice of Allowance for US Patent

(CALGARY, April 24, 2009) –TheraCarb Inc. is pleased to announce the receipt of a formal Notice of Allowance from the United States Patent Office on its patent application entitled, 'Multivalent inhibitors of Serum Amyloid P Component'.

This patent will cover certain novel compounds that may be useful for the development of therapies for the treatment of amyloid diseases such as Alzheimer's disease and maturity onset diabetes mellitus. "This represents another exciting application of PolyBAIT, the multivalent drug technology platform that TheraCarb is developing", says Dr. Murray Ratcliffe, Chief Operating Officer of TheraCarb.

TheraCarb maintains a portfolio of issued and pending patents to provide intellectual property protection for technologies in the areas of bacterial and fungal infectious diseases as well as CNS. An efficient patent filing and maintenance strategy helps protect new and existing technologies relevant to the pipeline.

About TheraCarb:

TheraCarb Inc. is an Alberta-based biotechnology company developing medicines for diseases with no known cure. With a vaccine and drug platform technology the company is focused on pre-clinical and early clinical proof of concept studies, developing late stage products through partnerships. TheraCarb's lead vaccine candidate is designed to treat infections from *Candida albicans*.

For more information contact:

Sanah Jowhari

TheraCarb Inc.

(403) 282-2030

sanah@theracarb.com

www.theracarb.com